Indeed, approximately 20% of epithelial ovarian cancer (EOC) patients exhibit mutations in breast cancer susceptibility gene 1 (BRCA1) and gene 2 (BRCA2), contributing to homologous recombination deficiency (HRD). The gene discussed is BRCA1; the disease is ovarian carcinoma.